Latest Ratios: P/E Ratio -1.8x · EV/EBITDA N/A · ROE -194.6%. (2021–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Market Cap | $11M | $33M | — | — | — |
| Enterprise Value | $11M | $34M | — | — | — |
| P/E Ratio → | -1.76 | — | — | — | — |
| P/S Ratio | 1.26 | 2.95 | — | — | — |
| P/B Ratio | 2.93 | 6.87 | — | — | — |
| P/FCF | — | — | — | — | — |
| P/OCF | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| EV / Revenue | — | 2.99 | — | — | — |
| EV / EBITDA | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — |
| EV / FCF | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Gross Margin | 77.7% | 77.7% | 77.6% | 75.9% | 79.6% |
| Operating Margin | -19.3% | -19.3% | 21.8% | 20.6% | 23.2% |
| Net Profit Margin | -106.8% | -106.8% | 20.6% | 18.4% | 18.6% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| ROE | -194.6% | -194.6% | 31.8% | 38.8% | 53.4% |
| ROA | -72.9% | -72.9% | 13.1% | 11.1% | 11.7% |
| ROIC | -21.5% | -21.5% | 15.4% | 12.6% | 15.1% |
| ROCE | -28.5% | -28.5% | 24.3% | 21.6% | 25.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Debt / Equity | 0.70 | 0.70 | 0.57 | 1.31 | 2.74 |
| Debt / EBITDA | — | — | 1.57 | 2.82 | 3.33 |
| Net Debt / Equity | — | 0.09 | 0.31 | 1.09 | 2.32 |
| Net Debt / EBITDA | — | — | 0.86 | 2.34 | 2.82 |
| Debt / FCF | — | — | 0.93 | 2.31 | 3.18 |
| Interest Coverage | -60.32 | -60.32 | 14.64 | 9.93 | 8.44 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Current Ratio | 1.23 | 1.23 | 2.26 | 2.28 | 2.18 |
| Quick Ratio | 1.19 | 1.19 | 2.25 | 2.27 | 2.17 |
| Cash Ratio | 0.28 | 0.28 | 0.27 | 0.19 | 0.22 |
| Asset Turnover | — | 0.67 | 0.62 | 0.63 | 0.63 |
| Inventory Turnover | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — |
| FCF Yield | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $2M | $1M | $1M | $1M |
Unsustainable capital burn rate
As reported in recent financial filings, BMGL trades at a P/B of 2.86, a multiple that appears disconnected from its negative ROE of -2.0% and suggests investors are pricing in future platform scalability rather than current underwriting performance or tangible book value accumulation.
The current P/B ratio implies a significant premium for a company that has yet to demonstrate a path to underwriting profitability. This valuation warrants further investigation, as it likely reflects speculative interest in the firm's medical technology segment rather than the underlying insurance or healthcare plan business.
Based on 2024Q4 data, BMGL recorded a combined ratio of 126.7%, which indicates that for every dollar of premium earned, the company is paying out significantly more in claims and expenses, thereby failing to achieve the underwriting profit necessary for long-term sustainability.
The 89.4% loss ratio suggests that the company's pricing or risk selection may be inadequate for the current medical cost environment. Without a material reduction in this ratio, the firm will continue to rely on external capital to bridge the gap between claims obligations and premium revenue.
According to the latest quarterly figures, the company maintains a debt-to-equity ratio of 0.70, which, while appearing conservative, masks the underlying pressure on the capital base caused by the persistent underwriting losses and the lack of a meaningful investment float to support operations.
The current leverage profile suggests that the company is operating with limited financial flexibility. Investors should monitor whether the firm can maintain its capital adequacy ratios as it continues to scale its specialist footprint without a corresponding improvement in underwriting margins.
As indicated by the company's 2024Q4 financial statements, the P/B ratio is a frequently misapplied metric for BMGL, as it obscures the rapid erosion of book value caused by the -106.78% net margin and the lack of high-quality, liquid invested assets backing the reserves.
Relying on P/B for an insurer in a startup phase ignores the reality that the book value is being depleted by operational losses rather than being supported by profitable underwriting. A more appropriate focus would be the burn rate relative to the remaining cash reserves, which provides a clearer picture of the firm's immediate survival risk.
Includes 30+ ratios · 4 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BMGL stock.
Basel Medical Group Ltd Ordinary Shares's current P/E ratio is -1.8x. This places it at the 50th percentile of its historical range.
Basel Medical Group Ltd Ordinary Shares's return on equity (ROE) is -194.6%. The historical average is -17.7%.
Based on historical data, Basel Medical Group Ltd Ordinary Shares is trading at a P/E of -1.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Basel Medical Group Ltd Ordinary Shares has 77.7% gross margin and -19.3% operating margin.